Abstract: The present invention relates to the discovery that non-traditional export of certain pro-inflammatory cytokines lacking a signal sequence from a cell can be inhibited by copper chelation and/or administration to the cell of a truncated form of S100A13 lacking the basic residue portion. Further, copper chelation inhibits, inter alia, neointima formation, macrophage infiltration and associated inflammation, cell proliferation, secretion of extracellular matrix, intimal thickening, adventitial angiogenesis, restenosis, and the like, associated with vascular vessel injury. Thus, the present invention provides novel methods of preventing and treating, and for identifying novel compounds also useful as therapeutics for, such conditions.

Abstract: The invention includes compounds of formula I:

Abstract: Compounds which may be used in the treatment and/or prevention of cancer have the formula (I) wherein: R1, R2, R3, R4, R5 and R6 independently represents H, alkyl, —CO2R′, aryl or alkylaryl, which latter two groups are optionally substituted on the aromatic ring; R′ represent alkyl, aryl or alkaryl; X is halo, H2O, (R′)(R″)SO, R′CO2— or (R′)(R″)C═O, where R″ represents alkyl, aryl or alkaryl; Y is a counterion; m is 0 or 1; q is 1, 2 or 3; C′ is C1 to C12 alkylene, optionally substituted in or on the alkylene chain, bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1; and A and B are: each independently N-donor nitrile ligands; or B is halo and A is an N-donor pyridine ligand, optionally substituted at one or more of the carbon atoms of the pyridine ring; or p is 0, A is NR7R8 and B is NR9R10, wherein R7, R8, R9 and R10 independently represent H or alkyl, and A and B are linked by an alkylene chain, optionally

Abstract: The present invention relates to a process for preparing enantiomerically enriched &agr;- and &bgr;-hydroxycarboxylic esters from the corresponding ketocarboxylic esters and also to catalysts usable therefor.

Abstract: Combinations of synthetic low molecular weight catalysts for the dismutation of superoxide and opioids are potent analgesics that are effective in elevating the pain threshold in hyperalgesic conditions.

Abstract: A metal complex and its use for binding or cleaving a nucleic acid. The metal complex has the formula: M is Pt, Pd, Ni, Co, or Cu; X is aryl, heteroaryl, cyclyl, or heterocyclyl; Y is halogen, tosylate, mesylate, triflate, pyrophosphate, or carboxylate; each of A1 and A2, independently, is N or C; each of A3 and A4, independently, is N, S, or O, wherein A1, A2, A3, and A4 taken together have one positive charge; and each of R1 and R2, independently, is alkyl, aryl, heteroaryl, alkoxyl, aryloxyl, heteroaryloxyl, alkoxylcarbonyl, aryloxylcarbonyl, or heteroaryloxylcarbonyl.

Abstract: The present invention relates to novel stabilized silver ion complexes having improved stability in aqueous solutions. The described stabilized silver-ion complex compositions comprise a silver-thiosulfate ion complex, a sulfite stabilizing agent either with or without a sulfite preservation agent. These carrier-free aqueous sulfite stabilized silver thiosulfate ion complex compositions have improved stability when exposed to an aqueous environment for extended periods. Consequently, these compositions have improved antibacterial, anti-viral and/or antifungal activity. These stabilized compositions can be used to coat a wound dressing, an ostomy appliance, an incontinence device, or other medical devices and impart long-term antimicrobial activity.

Abstract: A method is provided for treatment of an infective condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk producing animal or an ear. The method comprises administering an antibacterial agent to the organ via the exterior orifice and administering in combination therapy with the antibacterial agent a second agent that is an anti-inflammatory agent, an analgesic and/or an antipyretic. The antibacterial agent and, optionally, the second agent, are administered as a pharmaceutical composition further comprising a vehicle that comprises an amphipathic oil that is water dispersible and ethanol insoluble, microcrystalline wax and a pharmaceutically acceptable non-aqueous carrier. Also provided is such a composition comprising the antibacterial agent and the second agent.

Abstract: The present invention is drawn to an ephedra- and artificial stimulant-free energy promoting composition, comprising effective amounts of a magnesium amino acid chelate, a B vitamin, a pyruvate salt, and rhodiola. These ingredients work synergistically together to provide energy, without the use of artificial stimulants, caffeine, or ephedrine. Additional amino acid chelates can also be present, such as iron amino acid chelate, zinc amino acid chelate, copper amino acid chelate, manganese amino acid chelate, chromium amino acid chelate, and mixtures of second amino acid chelates.

Abstract: A method of enhancing regional body fat reduction is disclosed. The method includes topically applying a fat reduction topical composition on a region of a human body where a regional fat reduction is desired for a treatment period, and administering an amount of a fat reduction oral composition daily during the treatment period. The topical composition includes hydroglycolic fluid extract of Palmaria palmata, Laminaria digitata extract, mannitol, and a pharmaceutically acceptable carrier. The oral composition includes synephrine, methylxanthine, chromium, a herbal combination having diuretic effect and a pharmaceutically acceptable carrier.

Abstract: A microbicidal composition containing: (a) at least one sulfur-containing s-triazine; (b) at least one pyrithione metal salt; and (c) at least one additional microbicide selected from 2-alkyl-4-isothiazolin-3-ones and halopropynyl carbamates.

Abstract: Provided are a method for easily detecting phosphorylated peptides, namely, proteins, in samples derived from living organisms or the like, a method for selectively adsorbing the phosphorylated peptides, and compounds that are highly coordinated to the phosphorylated peptides and usable in the methods.

Abstract: A microbicidal composition containing: (a) at least one sulfur-containing s-triazine; and (b) at least one pyrithione metal salt.

Abstract: The invention provides a method for inhibiting c-jun activation in mammalian or avian cells comprising contacting the cells with a substance that inhibits the activity of Janus family kinase 3 (JAK-3). The invention also provides a therapeutic method for preventing or treating a pathological condition in a mammal wherein c-jun activation is implicated and inhibition of its activation is desired comprising administering to a mammal in need of such therapy, an effective amount of a substance that inhibits the activity of JAK-3. Novel compounds that are JAK-3 inhibitors, as well as pharmaceutical compositions comprising the compounds are also provided.

Abstract: Prophylactic treatment to reduce the incidence of common cold using formulations of zinc compounds with selected amino acids is described. The administration of such formulations to healthy individuals resulted in a statistically significant reduction in the incidence of common colds in healthy patients.

Abstract: The invention relates to copper-carbene complexes, to a process for preparing them and to their use in catalytic coupling reactions.

Abstract: The present invention relates to dietary supplementing methods useful for controlling obesity. More particularly, the invention relates to methods of administration of compositions containing defined chemical species useful for prevention and treatment of obesity. In a preferred embodiment, pharmaceutical compositions used in connection with the present invention comprise: (1) a zinc salt, (2) cyclo-Hispro and/or (3) arachidonic acid, and (4) at least one pharmaceutically acceptable excipient. More particularly, the invention relates to methods of manufacturing of preparing a soybean protein hydrolysate (SPH) comprising cyclo-Hispro.

Abstract: A method of treating Restless Leg Syndrome, includes administering to a subject an iron complex having an iron release rate greater than IDI. The iron release rate is determined at a concentration of at least 2,000 &mgr;g/dl.

Abstract: A series of dynamic platinum compounds for cancer treatment are described. The compounds may become active and inactive reversibly.

Abstract: The present invention relates to amidomalonate O,O′—Pt and N,O—Pt chelates and methods of preparing them in essentially pure form.

Abstract: The invention relates to a method of deriving a peptidomimetic of a biologically active metallopeptide, wherein the peptidomimetic includes at least one non-peptide ring structure defining a template space superimposable on a corresponding defined template space of the metallopeptide, and where the peptidomimetic further includes at least two elements independently including an amino acid residue, amino acid side chain moiety or derivative thereof, the elements defining and occupying a similar descriptor space as corresponding elements of the metallopeptide. The invention further relates to peptidomimetics with a template space heterocyclic ring structure, including 5-, 6- and 8-membered and 5-5- and 6-5-bicyclic fused ring structure melanocortin receptor-specific peptidomimetics.

Abstract: This invention concerns antimicrobial compositions that are useful for industrial applications.

Abstract: An antibacterial composition for medical tools made of a vinyl chloride resin, which comprises a specific cyclic organic phosphoric ester compound and a specific pyrithione compound and has excellent antibacterial properties; and a medical tool made of an antibacterial vinyl chloride resin obtained by adding the antibacterial composition to a vinyl chloride resin.

Abstract: Disclosed are combinations of soy protein and chromium in amounts effective to inhibit the loss of lean body mass of a subject under caloric restriction. Further combinations include corosolic acid and optionally additional chromium. Still further combinations include a dietary composition of Fucus vesiculosus, Gambogia garcinia, Apis mellifica, Badiaga, Calcarea carbonica, Passiflora incarnata, Baryta carbonica, Calcarea fluorica, Lycopodium clavatum, Berberis vulgaris, Leptandra virginica, Thuja occidentalis, Galium aparine, Urtica urens, Histaminum muriaticum, and Sabadilla. Compositions of the disclosed soy protein, chromium, and corosolic acid combinations are disclosed as are kits containing the disclosed combinations as well as methods of using the disclosed combinations and compositions for weight loss and the inhibition of the loss of lean body mass in a subject during weight loss.

Abstract: The present invention provides methods and compositions comprising one or more zinc ionophores for protecting tissue from the harmful effects of apoptosis in patients in need thereof. Concentrations of zinc-pyrithione and diethyldithiocarbamate in the picomolar to nanomolar range have a strong protective effect against apoptosis.

Abstract: A method for separating and purifying the active hematinic species present in iron-saccharidic complexes including sodium ferric gluconate complex in sucrose, ferric hydroxide-sucrose complex and ferric saccharate complex and others of similar form and function, based on separation of the iron-saccharidic complex from one or more excipients and, preferably, lyophilization. Separation of the iron-saccharidic complex permits its analytical quantification; further concentration or purification as a new and useful product; preparation of redesigned formulations for new and useful pharmaceuticals; and/or lyophilization.

Abstract: An oral composition, suitable as a hypoglycemic agent, includes an isolate from the leaves of Gymnema sylvestre, having a specified molecular weight. The isolate has a molecular weight at least about 3000 Daltons as determined by molecular weight cut-off filtration. Glucose metabolism in a human patient can be regulated by dosage forms that contain the aforesaid isolate from the leaves of Gymnema sylvestre, in combination with a non-metabolizable, water-swellable polysaccharide such as the exudate of Sterculia urens, and a water-soluble polysaccharide such as guar gum. Optionally, the present oral compositions can include a physiologically acceptable calcium source, a physiologically acceptable metal carbonate salt, a physiologically acceptable chromium salt, and/or a physiologically acceptable vanadium compound. In addition, antioxidants such as ascorbic acid, cholecalciferol, d-&agr;-tocopherol, the carotenoids, lycopene, lutein, and the like, can be included as well.

Abstract: Described is a method of using gadolinium-containing compounds as agents for neutron capture therapy to treat neoplastic cell growth. The subject is exposed to a gadolinium-containing compound for a time sufficient to allow the compound to accumulate in neoplastic cells. The subject is then exposed to a thermal and/or epithermal neutron flux, thereby initiating a neutron capture reaction in the gadolinium atoms that results in specific death of neoplastic cells.

Abstract: Combinations of synthetic low molecular weight catalysts for the dismutation of superoxide and Nonsteroidal Analgesic/Anti-Inflammatory Drugs (NSAIDs) are potent analgesics that are effective in elevating the pain threshold in hyperalgesic conditions.

Abstract: The invention provides methods for inhibiting oxidative degradation of pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient which methods comprise adding an oxidation-inhibiting amount of a ferrous ion source, preferably in the form of a pharmaceutical excipient, to the formulation. The invention further provides pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient and an oxidation-inhibiting amount of a ferrous iron source, preferably in the form of a pharmaceutical excipient. The invention still further provides for the use of a ferrous ion source as an anti-oxidant in pharmaceutical formulations.

Abstract: The equilibrium between G actin and F actin is shifted towards the F actin confirmation with compounds such as the ionic form of magnesium or potassium. The higher amount of F actin decreases the inhibition of nucleases such as DNAse I by monomeric G actin. The increased performance of the nuclease results in better treatment of patients suffering from cystic fibrosis or other diseases with viscous mucus.

Abstract: A nutritional supplement formulation for the enhancement of blood sugar regulation, prevention and treatment of insulin resistance, prevention and treatment of dysinsulinemia, prevention and treatment of Syndrome X, and reduction of diabetic complications is disclosed. The formulation combines herbs, minerals and vitamins known to reduce insulin resistance with herbs, minerals and vitamins known to reduce blood sugar levels.

Abstract: Chemicals which make not only a dark-red/light-red change of color but also a near-infrared/red change of luminescence via reversible adsorption/desorption of vapor of acetonitrile or ethanol, and therefore permit the observation of on-off change of visually effective luminescence and thus are useful as highly sensitive sensors. The chemicals are binuclear platinum (II) complexes of the following general formula: [Pt2(L)2(bpy)2]X2 or [Pt2(L)2(bpy)2]Y (wherein L is a bridging ligand selected from among 2-pyridinethiol anion, 2-quinolinethiol anion, 8-quinolinethiol anion and so on; bpy is 2,2-bipyridine; X is a monovalent anion; and Y is a bivalent anion), characterized by taking a syn form wherein the two bridging ligands (L) coordinate to one platinum ion at their respective sulfur atoms and to the other platinum ion at their respective nitrogen atoms.

Abstract: It is intended to provide foods such as health (supplementary) foods, nutrition (supplementary) foods and foods with health claims (foods for specified health uses and foods with nutrient function claims) containing zinc compositions which are less toxic and have a high insulin-like activity. Foods containing organic compounds capable of forming a complex with zinc and zinc sources. More specifically, foods such as health foods, health supplementary foods, nutrition foods nutrition supplementary foods and foods with health claims (foods for specified health uses and foods with nutrient function claims) containing organic compounds such as picolinic acid, L-amino acids, oligopeptides, niacin, maltol, etc. and organic zinc complexes or mineral acid salts of zinc containing these compounds as a ligand and having an effect of lowering blood glucose level.

Abstract: The formulation includes a combination of a chalcone, specifically, methylhydroxychalcone polymer, in the amount of 6 mg to 24 mg, and chromium, in the amount of 500 mcg to 2000 mcg. The formulation also includes a plurality of vitamins and nutrients, vitamins B6, C, E and K including green tea polyphenols and other nutrients.

Abstract: The present invention relates to pharmaceutical and veterinary compositions and methods using such compositions for the treatment of hypotension. Such compositions contain a catalyst for the dismutation of superoxide, including superoxide dismutase enzyme (SOD) and small molecular weight organic ligand mimics of that enzyme (SOD mimetics or SODms) which may be administered alone or in combination with a catecholamine pressor agent. Applications described include treatments for hypotension resulting from septic, cardiogenic, hypovolemic, anaphylactic or burn-induced shock treatments.

Abstract: Implantable medical devices using zinc, and methods therefore, provide one or more advantageous effects to a tissue. In one embodiment, at least one zinc-containing component is coupled with a stent via one or more zinc chelators to enhance resistance of the stent to plaque formation and in-stent restenosis. Elastin production may also be enhanced by devices coupled with zinc. Enhanced elastin production may be used, for example, to treat a blood vessel in location at or near an aneurysm. In some embodiments, both elastin production and plaque resistance are enhanced. For example, zinc may be applied via a gel or other carrier substance to a venous graft for enhancing elastin and resisting plaque formation. Implantable devices coupled with zinc may provide improved results of medical and surgical procedures involving implantable devices, thus reducing the need for repeat procedures.

Abstract: The present invention provides a method for the treatment of a viral infection in a patient by administration of a bis-peroxovanadium (bpV) compound, a potent class of phosphotyrosyl phosphatase inhibitors. The method can be utilized for the treatment of patients suffering from infections caused by viruses, such as the human immunodeficiency virus (HIV). The bpV compound may be used in combination with various immunomodulators and/or antiviral agents, in particular, 3TC of which it promotes the phosphorylation into the triphosphate form.

Abstract: The present invention provides a class of chemical compounds useful as efficacious drugs in the treatment of sickle cell disease and diseases characterized by unwanted or abnormal cell proliferation, and in particular inflammatory diseases associated with unwanted cellular proliferation. The active compounds are substituted triaryl methane compounds or analogues thereof where one or more of the aryl groups is replaced with a heteroaryl, cycloalkyl or heterocycloalkyl group and/or the tertiary carbon atom is replaced with a different atom such as Si, Ge, N or P. the compounds inhibit mammalian cell proliferation, inhibit the Gardos channel of erythrocytes, reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation.

Abstract: The present invention relates to a process for producing a sustained-release preparation comprising removing a solvent from an organic solvent solution containing a poorly water-soluble nonpeptidic physiologically active compound, a polyvalent metal compound and a biodegradable polymer, said physiologically active compound dissolved in an amount exceeding the solubility thereof in the organic solvent solution of biodegradable polymer in the absence of the polyvalent metal compound; a sustained-release preparation obtained by the process; a sustained-release solid pharmaceutical composition comprising a nonpeptidic physiologically active substance and a biodegradable polymer, wherein about 0.05% by weight or more, based on the weight of the composition, of a polyvalent metal is present on the surface of the composition; etc.

Abstract: A method for the protection of wood and other wood materials without affecting dimensional stability or surface integrity of the treated material is described. The method involves treating wood material with an iron salt and selected oxidants where the iron salt is preferably complexed with organic chelating ligands. Preferably, a microbicidal agent is also incorporated into the method to provide treated wood products that demonstrate excellent surface integrity, dimensional stability and retention of the infused microbicidal agents for extended periods of time without incurring the detrimental environmental effects of conventional chromium or copper-based inorganic salt preservation methods.

Abstract: The use of SOD mimics, particularly Mn(III) salen SOD mimics, for the treatment of AMD, DR, and retinal edema is disclosed.

Abstract: Disclosed is an improved composition and method for smoking cessation. The composition includes a candy base, sweetener, nicotine, (to satisfy nicotine cravings experienced by someone attempting to discontinue smoking), and chromium picolinate, (to address the issue of undesirable weight gain associated with smoking cessation.) The method includes selective substitution of the lollipop with the cigarette until smoking ceases.

Abstract: The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, in

Abstract: The invention relates to a compound of the general formula (I) 1

Abstract: Prophylactic treatment methods are disclosed. The methods can include contacting an object and/or an area of a subject with a metal-containing material to reduce the occurrence of a condition at the same area or a different area of the subject. The metal-containing material can be, for example, an antimicrobial material, an anti-biofilm metal-containing material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, an anti-proliferative material, an MMP modulating material, an atomically disordered, crystalline material, and/or a nanocrystalline material. In certain embodiments, the metal-containing material is an atomically disordered, nanocrystalline silver-containing material.

Abstract: Compositions for treating or preventing fat maldistribution or hyperlipidemia resulting from anti-retroviral treatment of HIV-1 infection are disclosed. The compositions contain a conjugated fatty acid or alcohol and at least one member selected from the group consisting of a thiol-containing compound and a bioavailable form of trivalent chromium. Methods of treating a subject suffering from HIV-associated fat maldistribution or hyperlipidemia by administering a composition that includes a conjugated fatty acid or conjugated fatty alcohol and at least one member selected from the group consisting of a thiol-containing compound and a bioavailable form of trivalent chromium are similarly provided.

Abstract: The invention provides methods for treating cancer and compounds that are useful for the treatment of tumors, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates useful for preparing the compounds.

Abstract: The addition of low concentrations of combinations of water-soluble organic salts of zinc to gels, creams, lotions or ointments can increase the ability of these products to reduce or prevent exogenous irritants from causing irritation of the underlying substrate. The addition of low concentrations of combinations of water-soluble organic zinc salts to these gels, creams, lotions or ointments also can reduce the irritation of skin or mucous membranes caused by the addition of potentially-irritating substances such as spermicides, microbicides, fungicides or other therapeutic agents to the gel, cream, lotion or ointment. The advantages of this anti-irritant approach over others, which generally employ high concentrations of single zinc salts, are the reduced potential for zinc toxicity, the reduced potential for toxicity related to zinc itself, and the preservation of the desirable biological properties of potentially-irritating therapeutic substances added to the gel, cream, lotion or ointment.

Abstract: The present invention concerns the use of methods and compositions for the treatment of cancer and other hyperproliferative diseases. In certain embodiments, methods are described for the treatment of cancer and/or hyperproliferative diseases by administration of compositions containing at least one platinum complex alone or in combination with a modulator of glutathione. In particular, the methods may be used to treat cisplatin or carboplatin resistant tumor cells.